Adebrelimab plus chemotherapy improves overall survival in extensive-stage small-cell lung cancer
1. The adebrelimab group had an improved overall survival, higher objective response rate and an increased progression-free survival. 2. Adverse ...
1. The adebrelimab group had an improved overall survival, higher objective response rate and an increased progression-free survival. 2. Adverse ...
1. The median overall survival for nivolumab was 16.4 months and for sorafenib was 14.7 months 2. Patients receiving nivolumab ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.